Get the Stockscreener App
0.5662
5.48%
0.05
China Pharma Holdings Inc. stock is traded at $0.5662, with a volume of 0.
It is up +5.48% in the last 24 hours and up +3.17% over the past month.
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, cephalosporin oral solutions, and granules. The company's products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Anhydroandrographolide for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; and Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. is headquartered in Haikou, the People's Republic of China.
See More
Previous Close:
$0.6162
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$3.09M
Revenue:
$4.05M
Net Income/Loss:
$-3.19M
P/E Ratio:
-0.5492
EPS:
-1.0309
Net Cash Flow:
$-169.60K
1W Performance:
+9.87%
1M Performance:
+3.17%
6M Performance:
-64.22%
1Y Performance:
-75.84%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.6162
52-Week Range:
$0.00
$3.18
China Pharma Holdings Inc. Stock (CPHI) Company Profile
Name
China Pharma Holdings Inc.
Sector
Phone
86 898 6681 1730
Address
No. 17, Jinpan Road, Second Floor, Haikou
Compare CPHI vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPHI
China Pharma Holdings Inc.
|
0.00 | 3.09M | 4.05M | -3.19M | -169.60K | -1.0309 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.82 | 57.24B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
119.09 | 50.57B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.14 | 44.54B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.93 | 35.49B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
539.03 | 23.87B | 3.13B | 1.27B | 1.12B | 26.39 |
China Pharma Holdings Inc. Stock (CPHI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-10 | Initiated | Rodman & Renshaw | Mkt Outperform |
China Pharma Holdings Inc. Stock (CPHI) Latest News
Volume Recap: What are the analyst revisions for Amdocs LimitedIs CTEV stock a good investment in YEARProduct Launch & AI Based Buy and Sell Signals - baoquankhu1.vn
Can China Pharma Holdings Inc lead its sector in growth2026 Momentum Check & Target Return Focused Picks - baoquankhu1.vn
Will Pony AI Inc. Depositary Receipt stock continue dividend increases2026 Support & Resistance & Reliable Intraday Trade Plans - Naître et grandir
How GreenTree Hospitality Group Ltd. American stock performs during market turbulencePortfolio Risk Report & Weekly Return Optimization Plans - Naître et grandir
Volume Report: Is Central Plains Bancshares Inc backed by strong institutional buyingRisk Management & Community Consensus Trade Alerts - baoquankhu1.vn
Is Southland Holdings Inc. Equity Warrant stock a dividend growth opportunityIPO Watch & Risk Controlled Daily Trade Plans - Naître et grandir
Fed Watch: Is China Pharma Holdings Incs ROE strong enoughJuly 2025 Trade Ideas & Stepwise Trade Execution Plans - baoquankhu1.vn
Inflation Data: How does China Pharma Holdings Inc perform in inflationary periodsBuy Signal & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Trade Recap: Can China Pharma Holdings Inc expand into new marketsJuly 2025 Intraday Action & Community Consensus Trade Signals - baoquankhu1.vn
China Pharma Expands R&D Portfolio With Patent Acquisition - TipRanks
Quarterly Risk: Can China Pharma Holdings Inc keep up with sector leadersJuly 2025 WrapUp & Fast Gain Stock Trading Tips - baoquankhu1.vn
getLinesFromResByArray error: size == 0 - mfd.ru
Naproxen Patches Market Growth Fueled by Shift from Oral Nsaids, Forecast to 2035News and Statistics - IndexBox
CPHI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
GLMD PE Ratio & Valuation, Is GLMD Overvalued - Intellectia AI
Inflation Data: Is Blackstone Inc affected by consumer sentimentQuarterly Earnings Summary & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Risk Check: Is China Pharma Holdings Inc part of any ETFQuarterly Growth Report & Smart Investment Allocation Insights - baoquankhu1.vn
Risk Analysis: Can NESRW lead its sector in growthShare Buyback & Trade Opportunity Analysis - baoquankhu1.vn
BIT Capital GmbH Reduces Holdings in BridgeBio Pharma, Inc. $BBIO - Defense World
CPHI Should I Buy - Intellectia AI
Winners Losers: Is GoldMining Inc part of any ETFMarket Sentiment Summary & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
The China factor: US pharma group campaigns for increased competitiveness - Yahoo Finance
PAPLD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
AI Drug Discovery Push And New Kidney Drug Trial Could Be A Game Changer For China Medical System Holdings (SEHK:867) - simplywall.st
Profit Review: Should I set a stop loss on SGRPLayoff News & Technical Buy Zone Confirmation - baoquankhu1.vn
00863 Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Most and least shorted healthcare stocks with up to $2B market cap - Seeking Alpha
Can China Pharma Holdings Inc. stock maintain growth trajectory2025 Investor Takeaways & Long-Term Safe Return Strategies - mfd.ru
Will China Pharma Holdings Inc. stock maintain momentum in 2025Gap Up & Verified Entry Point Detection - mfd.ru
What margin trends mean for China Pharma Holdings Inc. stockJuly 2025 Trends & Technical Pattern Based Signals - mfd.ru
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
China Medical System Expands AI Drug Pipeline As Valuation Gap Persists - simplywall.st
Published on: 2026-02-12 19:55:00 - mfd.ru
Is Gold Royalty Corp. currently under institutional pressure2025 Top Gainers & Stock Portfolio Risk Control - mfd.ru
Is China Pharma Holdings Inc. stock trending bullish2025 Key Highlights & AI Driven Price Predictions - mfd.ru
What’s next for Athira Pharma Inc. stockCPI Data & Pattern Based Trade Signal System - mfd.ru
Can China Pharma Holdings Inc. expand its profit marginsTrade Risk Report & Long-Term Safe Investment Ideas - mfd.ru
China Pharma to acquire patent through $8.82 million stock issuance By Investing.com - Investing.com India
China Pharma to acquire patent through $8.82 million stock issuance - Investing.com Nigeria
China Pharma Acquires Topiroxostat Patent Via Equity Issuance - TipRanks
Risk Check: Is PGEN stock a hidden gemPortfolio Risk Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Aug Reactions: Can China Pharma Holdings Inc stock outperform in a bear marketJuly 2025 Spike Watch & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Ascentage Pharma Receives Clearance from China’s CDE for New Drug - Yahoo Finance
Ascentage Pharma Group International Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - marketscreener.com
Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - Yahoo Finance
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
DSS, INC. (DSS) - MSN
Risk Off: Is GPATW part of any major index2025 Major Catalysts & Daily Oversold Bounce Ideas - baoquankhu1.vn
12 Health Care Stocks Moving In Monday's After-Market Session - Sahm
China Pharma Holdings acquires patent in stock deal - MSN
What China SXT's 1-for-150 share consolidation means for holders - Stock Titan
China Pharma Holdings Inc. Stock (CPHI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.00%
2.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):